Evidence map›Paper›PMID 31856411›Full record

ArticleCancer medicine2020

Methylation of CpG 5962 in L1 of the human papillomavirus 16 genome as a potential predictive marker for viral persistence: A prospective large cohort study using cervical swab samples.

Jasmin Fertey, Jörg Hagmann, Hans-Joachim Ruscheweyh, Christian Munk, Susanne Kjaer, Daniel Huson, Juliane Haedicke-Jarboui, Frank Stubenrauch, Thomas Iftner

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. HPV16 Genomes:Current genomics · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Jasmin FerteyMedical Virology, Institute of Medical Virology, University Hospital of Tuebingen, Tuebingen, Germany.ORCID 0000-0001-5424-3807
Jörg HagmannDepartment of Molecular Biology, Max Planck Institute for Developmental Biology, Tuebingen, Germany.ORCID 0000-0002-7232-3103
Hans-Joachim RuscheweyhCentre for Bioinformatics, Tuebingen University, Tuebingen, Germany.ORCID 0000-0001-7473-6086
Christian MunkUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0001-5248-5431
Susanne KjaerUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0002-8347-1398
Daniel HusonCentre for Bioinformatics, Tuebingen University, Tuebingen, Germany.
Juliane Haedicke-JarbouiMedical Virology, Institute of Medical Virology, University Hospital of Tuebingen, Tuebingen, Germany.ORCID 0000-0001-8637-0931
Frank StubenrauchMedical Virology, Institute of Medical Virology, University Hospital of Tuebingen, Tuebingen, Germany.ORCID 0000-0002-6685-299X
Thomas IftnerMedical Virology, Institute of Medical Virology, University Hospital of Tuebingen, Tuebingen, Germany.
Institute of Virology of the Slovak Academy of Sciences · SKDanish Cancer Society · DKSTZ eyetrial · DEMax Planck Institute for Developmental Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several studies have demonstrated that the viral genome can be methylated by the host cell during progression from persistent infection to cervical cancer. The aim of this study was to investigate whether methylation at a specific site could predict the development of viral persistence and whether viral load shows a correlation with specific methylation patterns. HPV16-positive samples from women aged 20-29 years (n = 99) with a follow-up time of 13 years, were included from a Danish cohort comprising 11 088 women. Viral load was measured by real-time PCR and methylation status was determined for 39 CpG sites in the upstream regulatory region (URR), E6/E7, and L1 region of HPV16 by next-generation sequencing. Participants were divided into two groups according to whether they were persistently (≥ 24 months) or transiently HPV16 infected. The general methylation status was significantly different between women with a persistent and women with a transient infection outcome (P = .025). One site located in L1 (nt. 5962) was statistically significantly (P = .00048) different in the methylation status after correction using the Holm-Sidak method (alpha = 0.05). Correlation analyses of samples from HPV16 persistently infected women suggest that methylation is higher although viral load is lower. This study indicates that methylation at position 5962 of the HPV16 genome within the L1 gene might be a predictive marker for the development of a persistent HPV16 infection.

Indexed as

DNA MethylationAdultCapsid ProteinsCervix UteriCpG IslandsDenmarkDNA, ViralFemaleFollow-Up StudiesGenes, ViralHuman papillomavirus 16HumansPapillomavirus InfectionsSequence Analysis, DNAUterine Cervical NeoplasmsVaginal SmearsCapsid ProteinsDNA, ViralL1 protein, Human papillomavirus type 6BiomarkerDNA MethylationHPV16Persistence

Identifiers

PMID31856411
PMCPMC6997067
OpenAlexW2995462099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.